ELEVATED LEVELS OF ENDOTHELIN-1 ARE ASSOCIATED WITH HIV-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION  by Parikh, Rushi et al.
Pulmonary Hypertension and Venous Thrombo-embolic Disease
A1543
JACC March 17, 2015
Volume 65, Issue 10S
elevated levels oF endothelIn-1 are assocIated wIth hIv-assocIated pulmonary 
arterIal hypertensIon
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 10:00 a.m.-10:45 a.m.
Session Title: Epidemiology and Pathogenic Pathways in Pulmonary Arterial Hypertension
Abstract Category: 24.  Pulmonary Hypertension and Pulmonary Thrombo-embolic Disease
Presentation Number: 1110-175
Authors: Rushi Parikh, Yifei Ma, Rebecca Scherzer, Amanda Heringer, John MacGregor, Jeffrey Martin, Steven Deeks, Peter Ganz, 
Priscilla Hsue, Stanford University, Palo Alto, CA, USA, University of California, San Francisco, San Francisco, CA, USA
Background: Infection with the human immunodeficiency virus (HIV) is an independent risk factor for pulmonary arterial hypertension 
(PAH), but the underlying pathogenesis remains unclear. Endothelin-1 (ET-1) is a robust vasoconstrictor and key mediator of pulmonary 
vascular homeostasis. In other forms of PAH, ET-1 predicts disease severity and endothelin receptor antagonists are central to treatment. 
Endothelin receptor antagonists improve clinical and hemodynamic parameters in HIV-associated PAH, but the direct relationship between 
ET-1 and pulmonary artery pressure in HIV-infected individuals has not been studied.
methods: We measured ET-1 and estimated pulmonary artery systolic pressure (PASP) with transthoracic echocardiography in 106 
HIV-infected individuals. Participants with a PASP ≥ 30 mmHg (n=65) underwent right heart catheterization. We conducted multivariable 
analysis to identify factors associated with elevated PASP on echocardiography and PAH on right heart catheterization.
results: Among 106 HIV-infected participants, 80% were male, the median age was 52 years, 77% were on antiretroviral therapy, and 
8.5% had known PAH. ET-1 was associated with both higher values of PASP [14% per 0.1 pg/mL increase in ET-1, p=0.05] and PASP ≥ 30 
mmHg [PR (prevalence ratio)=1.24, p=0.012] on echocardiography after multivariable adjustment for PAH risk factors. In adjusted analyses 
among the 65 individuals who underwent right heart catheterization, ET-1 was similarly associated with both higher values of mean 
pulmonary artery pressure and PAH (34%, p=0.003 and PR=2.43, p=0.032, respectively).
conclusion:  Higher levels of ET-1 are independently associated with HIV-associated PAH. Our findings suggest that excessive ET-1 
production in the setting of HIV infection impairs pulmonary endothelial function and is a key contributor to the development of PAH.
